Akamatsu, Hiroaki
Ninomiya, Kiichiro
Kenmotsu, Hirotsugu
Morise, Masahiro
Daga, Haruko
Goto, Yasushi
Kozuki, Toshiyuki
Miura, Satoru
Sasaki, Takaaki
Tamiya, Akihiro
Teraoka, Shunsuke
Tsubata, Yukari
Yoshioka, Hiroshige
Hattori, Yoshihiro
Imamura, Chiyo K.
Katsuya, Yuki
Matsui, Reiko
Minegishi, Yuji
Mizugaki, Hidenori
Nosaki, Kaname
Okuma, Yusuke
Sakamoto, Setsuko
Sone, Takashi
Tanaka, Kentaro
Umemura, Shigeki
Yamanaka, Takeharu
Amano, Shinsuke
Hasegawa, Kazuo
Morita, Satoshi
Nakajima, Kazuko
Maemondo, Makoto
Seto, Takashi
Yamamoto, Nobuyuki
Funding for this research was provided by:
Japanese Lung Cancer Society
Article History
Received: 22 February 2019
Accepted: 6 March 2019
First Online: 2 May 2019
Compliance with ethical standards
:
: Hiroaki Akamatsu received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly, MSD, Ono Pharmaceutical Co. Ltd, Pfizer, and Taiho Pharmaceutical Co. Ltd. He received research funding from MSD. Kiichiro Ninomiya received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, and MSD. Hirotsugu Kenmotsu received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd. Boeringer Ingelheim, Eli Lilly K.K., Kyowa Hakko Kirin Co. Ltd., Bristol-Myers Squibb, MSD, and Novartis Pharma K.K. He also received research funding from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd, and Boeringer Ingelheim. Masahiro Morise received honoraria from AstraZeneca, Chugai Pharmaceutical Co. Ltd, Eli Lilly, MSD, Ono Pharmaceutical Co. Ltd, and Pfizer. He also received research funding from AstraZeneca K.K., Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd, Pfizer, Ono Pharmaceutical Co. Ltd., Merck Serono, Kissei, Novartis and Taiho Pharmaceutical Co. Ltd. Haruko Daga received honoraria from Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd, and MSD. Yasushi Goto received honoraria from AstraZeneca, Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical Co. Ltd., Bristol Myers Squibb, Pfizer, MSD, Shionogi Pharma and Novartis. He also received research funding from Abbvie, Eli Lilly, Taiho Pharmaceutical, Bristol Myers Squibb, and Ono Pharmaceutical Co. Ltd. Toshiyuki Kozuki received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly, Kyowa Hakko Kirin Co, MSD, Nippon Kayaku, Ono Pharmaceutical Co. Ltd, Pfizer and Taiho Pharmaceutical Co. Ltd. He received research funding from AstraZeneca Chugai Pharmaceutical Co. Ltd, Eli Lilly and Merck Serono. Satoru Miura received honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd, Eli Lilly and MSD. Takaaki Sasaki received honoraria from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Co. Ltd., Eli Lilly and Novartis. He received research funding from Boehringer Ingelheim and Pfizer. Akihiro Tamiya received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd. and Eli Lilly. He received research funding from AstraZeneca, Bristol-Myers Squibb and Ono Pharmaceutical Co. Ltd. Yukari Tsubata received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Co. Ltd. and Kyowa Hakko Kirin. She received research funding from Daiichi Sankyo Co. Ltd. and Ono Pharmaceutical Co. Ltd. Hiroshige Yoshioka received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly, MSD, Novartis, Ono Pharmaceutical Co. Ltd., Pfizer, and Taiho Pharmaceutical Co. Ltd. Yoshihiro Hattori received honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd, Eli Lilly, MSD, Novartis, Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd. He received research funding from MSD and Ono Pharmaceutical Co. Ltd. Hidenori Mizugaki received honoraria from AstraZeneca, Boehringer Ingelheim, and Chugai Pharmaceutical Co. Ltd. He received research funding from Boehringer Ingelheim. Kaname Nosaki received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly, Kyowa Hakko Kirin, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical Co. Ltd., Pfizer, and Taiho Pharmaceutical Co. Ltd. He received research funding from MSD and Novartis. Yusuke Okuma received honoraria from Boehringer Ingelheim, AstraZeneca, MSD, Novartis, Taiho Pharmaceutical Co. Ltd, and Eli-Lilly. He received research funding from Chugai Pharmaceutical Co. Ltd and Takeda Pharmaceutical Co. Ltd. Kentaro Tanaka received honoraria from Chugai Pharmaceutical Co. Ltd. Shigeki Umemura received research funding from MSD. Takeharu Yamanaka received honoraria from Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd, Taiho Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd. He received research funding from Taiho Pharmaceutical Co. Ltd and Takeda Pharmaceutical Co. Ltd. Satoshi Morita received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly, MSD, Ono Pharmaceutical Co. Ltd., Pfizer, and Taiho Pharmaceutical Co. Ltd. He received research funding from Boehringer Ingelheim. Makoto Maemondo received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly, MSD, Novartis, Ono Pharmaceutical Co. Ltd., Pfizer, and Taiho Pharmaceutical Co. Ltd. He received research funding from Boehringer Ingelheim. Takashi Seto received honoraria from Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly, Kissei Pharmaceutical Co. Ltd, MSD, Novartis, Ono Pharmaceutical Co. Ltd., Pfizer, Roche Singapore, Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Thermo Fischer Scientific and Yakult Honsha Co. Ltd. He received research funding from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo, Eisai, Eli Lilly, Kissei Pharmaceutical Co. Ltd, LOXO Oncology, Merck Serono, MSD, Novartis, Pfizer and Takeda Pharmaceutical Co. Ltd. Nobuyuki Yamamoto received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Ono Pharmaceutical Co. Ltd., Pfizer, Taiho Pharmaceutical Co. Ltd. and Yakult Honsha Co. Ltd. He received research funding from Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd, Eli Lilly, and MSD. Others are no conflicts of interest.